Quantitative Insights

Chicago, IL, United States All United States companies → — Founded 2010

Imaging AI Specialist Specialty-Focused AI

Oncology Radiology

Oncology AI Radiology & Imaging AI

Acquired (previously received a Grant and was a University Spin-Out) — Undisclosed

Website Claim this company

Products

QuantX

Quantitative Insights

Oncology AI

QuantX by Quantitative Insights is an FDA-cleared AI-driven software platform for computer-aided diagnosis (CADx) of breast abnormalities using MRI, designed to enhance diagnostic accuracy and efficiency for radiologists.

See all 1 product →

About Quantitative Insights

Quantitative Insights was a healthcare AI company that developed a computer-aided diagnosis (CAD) system called QuantX, specifically designed to assist radiologists in the more accurate and efficient diagnosis of breast cancer. The company’s platform leveraged machine learning and advanced imaging analysis, integrating a deep database of historical cases to improve both the speed and accuracy of breast abnormality evaluations. Their technology aimed to provide an intuitive workstation for radiologists, enhancing patient management services through advanced research and imaging capabilities.

In July 2019, Quantitative Insights was acquired by Qlarity Imaging. Prior to its acquisition, the company had gained the industry’s first FDA clearance for a machine learning-driven cancer diagnosis system, as indicated by the provided PR Newswire link from 2017. Its focus remained on applying artificial intelligence and machine learning to critical areas within healthcare, particularly in oncology and diagnostic imaging.

What Physicians Need to Know

AI-Driven Cancer Diagnosis

Quantitative Insights specializes in developing machine learning-driven computer-aided diagnosis (CAD) platforms for cancer, initially focusing on breast abnormalities.

First FDA Clearance

Their flagship product, QuantXu2122, was the industry's first computer-aided diagnosis platform incorporating machine learning to receive FDA clearance for evaluating breast abnormalities.

Enhanced Diagnostic Performance

Clinical studies demonstrated that their technology significantly improves radiologists' diagnostic performance, leading to faster and more accurate diagnoses.

Physician Tip

For physicians, Quantitative Insights' technology, particularly QuantX, offers a significant advantage by augmenting diagnostic capabilities. It provides valuable additional information for multi-modality breast imaging decision support, increasing diagnostic confidence and improving reading times. The system has been shown to reduce missed breast cancers by 39% and achieve a 20% overall diagnostic improvement, enabling more personalized treatments and better patient outcomes. This AI tool is designed to work in conjunction with radiologists, not replace them, by providing advanced analytics and similarity assessments to a robust database of clinically documented pathologies.

Quantitative Insights' core product, QuantX, is a software platform designed to integrate with existing imaging workflows, providing advanced analytics and machine learning capabilities for decision support in breast imaging. It leverages quantitative imaging (radiomics) solutions.

At a glance

Founded 2010

HQ Chicago, IL, United States · United States

Team size Unknown

CEO Not applicable (company acquired); Founders include Brian Luerssen, Maryellen Giger, and Robert Tomek

Funding Acquired (previously received a Grant and was a University Spin-Out) — Undisclosed

Products 1

Visit site

Products by Quantitative Insights

1 product in the directory

QuantX

Quantitative Insights

Oncology AI

What the Web Says

Quantitative Insights, known for its QuantX product, received the industry's first FDA clearance for machine learning-driven cancer diagnosis, specifically for breast cancer. While this marks a significant technological advancement and positive industry recognition, public reviews from common platforms like G2, Glassdoor, Capterra, and Reddit are notably absent or extremely limited, making it difficult to assess widespread product satisfaction or employee experience.

Overall: Mixed

Strengths

First FDA clearance for machine learning-driven cancer diagnosis (QuantX)
Significant technological innovation in healthcare AI
Potential to improve accuracy and efficiency in cancer diagnosis
Positive recognition from regulatory bodies (FDA)
Addresses a critical need in medical imaging and diagnostics

Limitations

Lack of readily available product reviews on major platforms (G2, Capterra)
No discernible employee reviews on Glassdoor
Limited public discussion or reviews on Reddit
Difficulty in assessing user experience or company culture due to lack of data
Specific product features and user interface details are not widely reviewed

Based on reviews from: PRNewswire (for FDA clearance announcement), G2 (no relevant reviews found), Glassdoor (no relevant reviews found), Capterra (no relevant reviews found), Reddit (no significant discussions found)

Last updated: 2026-07-19

Videos

News, demos, and interviews about Quantitative Insights.

Loading videos...

Videos load interactively. If none appear, search YouTube for Quantitative Insights →

View all on YouTube

Press & Coverage

PR Newswire

Quantitative Insights Gains Industry's First FDA Clearance for Machine Learning Driven Cancer Diagnosis

Quantitative Insights received the first FDA clearance for a machine learning-driven cancer diagnosis system, QuantX, which assists radiologists in detecting breast cancer. The system uses AI to evaluate breast abnormalities from MRIs and medical data, aiming to improve diagnostic accuracy and reduce false negatives.

2017-07

Science and Enterprise

FDA Clears Algorithm-Assisted Cancer Diagnosis

The FDA cleared QuantX, a diagnostics system from Quantitative Insights that uses machine learning to help radiologists detect breast cancer, reducing false negatives by 39% in a clinical study. This system is a Class 2 device and was cleared through the de novo classification pathway.

2017-07

Institute for Translational Medicine (ITM)

FDA Clears ITM Investigator's Company's Computer-Aided Cancer Diagnosis Platform

Quantitative Insights, a company co-founded by ITM investigator Maryellen Giger, PhD, received FDA clearance for QuantX, its machine learning-driven platform for breast cancer diagnosis. The software evaluates MRIs and medical data to provide a 'QI score,' aiming for faster and more accurate detection.

2017-07

Fast Company

This AI breast cancer diagnostic tool is the first to get FDA clearance

QuantX, developed by Quantitative Insights and later acquired by Qlarity Imaging (Paragon Biosciences), was the first AI-powered breast cancer diagnosis system to receive FDA clearance. Clinical studies showed it improved radiologists' interpretation of MRIs, leading to a 39% reduction in missed breast cancers.

2019-07

UChicago Medicine

Artificial intelligence software for breast cancer diagnosis makes TIME's list of Best Inventions for 2019

QuantX, the FDA-cleared AI software for breast cancer diagnosis based on research by Maryellen Giger, PhD, at the University of Chicago, was named one of TIME's Best Inventions for 2019. It aims to reduce missed cancers and false positives by analyzing breast MRIs.

2019-12

Medical Product Outsourcing

FDA-Cleared Artificial Intelligence Breast Cancer Diagnosis System Launched by Paragon Biosciences

Paragon Biosciences launched Qlarity Imaging, which acquired QuantX, the first FDA-cleared AI-powered breast cancer diagnosis system. QuantX, initially developed at the University of Chicago, demonstrated a 39% reduction in missed breast cancers in clinical studies.

2019-09

Polsky Center for Entrepreneurship and Innovation

Quantitative Insights Gaining Ground

Quantitative Insights, co-founded by Brian Luerssen and James Krocak, licensed intellectual property from the University of Chicago for its CADx platform. The company received an Innovation Fund award, was a finalist in the New Venture Challenge, and secured a $150,000 SBIR grant from the National Science Foundation.

2011-12

Tracxn

Quantitative Insights Funding Rounds, Valuation & Investors

Quantitative Insights has raised a total of $150K from one grant round on November 16, 2010, with the National Science Foundation as the sole institutional investor.

2010-11

Frequently Asked Questions

What specific AI products or solutions does Quality Insights (QAI) offer to healthcare organizations?

Quality Insights offers an advanced AI-driven framework, QAI, that provides high-value insights and supports decision-making for federal and state healthcare programs, providers, and participants. Their secure platform enables visual data engagement, offering QAI-powered dashboards for tracking quality metrics, an ROI Calculator, and tools for data collection and infrastructure assessments. They have also developed an AI model to improve emergency department triage by incorporating uncertainty into clinical predictions.

How does Quality Insights (QAI) ensure its AI solutions comply with healthcare regulations and data privacy standards like HIPAA?

Quality Insights' QAI framework is designed to ensure data security and compliance, aiming to lower liability and improve the quality of care across healthcare networks. While specific HIPAA certifications for QAI are not detailed, the company emphasizes regulatory compliance and offers services like compliance reporting. In general, robust healthcare AI solutions adhere to HIPAA through measures like data encryption, access controls, and regular risk assessments.

What are the typical pricing models for Quality Insights (QAI)'s healthcare AI solutions?

The search results do not specify the exact pricing models for Quality Insights' QAI solutions. However, in the broader healthcare AI industry, decision-makers often prefer transparent and predictable hybrid pricing models, combining a base fee with variable components based on clinically meaningful units like per patient or per test. Integration, training, and ongoing support are generally considered integral components of the overall value and cost.

What kind of support and training does Quality Insights (QAI) provide to healthcare organizations implementing their AI platforms?

Quality Insights provides comprehensive support and training, including hands-on implementation assistance and extensive educational programs. These offerings encompass large-scale webinars, custom e-learning modules, and continuing education credits across various disciplines. They also offer customized consulting services focused on performance improvement and workflow optimization.

Does Quality Insights (QAI) engage in partnerships with other healthcare technology vendors or organizations?

Yes, Quality Insights actively engages in partnerships, working with healthcare providers, public agencies, and community organizations at both national and local levels. They have established nearly 500 community-based partnerships and collaborate with government clients, healthcare providers, and program participants to improve health outcomes.

What indicates the long-term stability and reliability of Quality Insights (QAI) as a healthcare AI partner?

Quality Insights has a strong foundation, operating for over 50 years as a nonprofit dedicated to improving health outcomes. They have a proven track record of driving significant improvements, impacting millions of patients and Medicare beneficiaries, and achieving substantial cost savings through their initiatives. The organization is committed to continuous innovation and collaboration, indicating a stable and reliable presence in the healthcare landscape.

Related Companies

Suggest an Edit →